Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733506 | 0.92 | DYRK1A (0.67) | DYRK1ADYRK1BABCG2EGFRHDAC3 | |
| SCHEMBL14733462 | 0.88 | DYRK1A (0.64) | DYRK1ADYRK1BEGFR | |
| SCHEMBL16038266 | 0.87 | DYRK1A (0.60) | DYRK1ADYRK1BABCG2EGFR | |
| SCHEMBL14733542 | 0.86 | DYRK1A (0.68) | DYRK1ADYRK1BABCG2 | |
| SCHEMBL17060597 | 0.84 | DYRK1A (0.73) | DYRK1ADYRK1BABCG2EGFRHDAC3 | |
| SCHEMBL14733536 | 0.83 | DYRK1A (1.00) | DYRK1ADYRK1B | |
| SCHEMBL14733493 | 0.82 | DYRK1A (0.63) | DYRK1ADYRK1B | |
| SCHEMBL14733529 | 0.80 | DYRK1A (0.62) | DYRK1ADYRK1B | |
| SCHEMBL14733587 | 0.80 | DYRK1A (0.62) | DYRK1ADYRK1B | |
| SCHEMBL14733490 | 0.80 | DYRK1A (0.61) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013026806-A1 | DYRK1 INHIBITORS AND USES THEREOF | EXONHIT SA (FR) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK1B 2/4885ABCG2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.